# Peganum harmala (Syrian Rue)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/peganum-harmala
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-19
**Evidence Score:** 4 / 10
**Category:** Middle Eastern
**Also Known As:** Peganum harmala L., Wild rue, African rue, Harmal, Esphand, Esfand, Steppenraute, Rue sauvage

## Overview

Peganum harmala contains beta-carboline alkaloids including harmine and harmaline that inhibit monoamine oxidase enzymes. These compounds may influence [neurotransmitter](/ingredients/condition/cognitive) [metabolism](/ingredients/condition/weight-management) and glucose regulation through PPARγ pathway modulation.

## Health Benefits

• May support blood sugar regulation through PPARγ pathway modulation (preliminary animal/in-vitro evidence only)
• Contains monoamine oxidase inhibiting compounds that could influence mood pathways (mechanistic studies, no human trials)
• Traditional use for various conditions in Iranian and North African medicine (historical use only, no clinical validation)
• Potential [anti-inflammatory](/ingredients/condition/inflammation) properties through Wnt signaling inhibition (in-vitro evidence only)
• May influence metabolic processes via cytochrome P450 enzyme modulation (pharmacological data only)

## Mechanism of Action

The primary bioactive compounds harmine, harmaline, and harmalol reversibly inhibit monoamine oxidase A and B enzymes, potentially increasing [serotonin](/ingredients/condition/mood), dopamine, and norepinephrine levels. These beta-carboline alkaloids also modulate PPARγ receptors, which regulate glucose metabolism and [insulin sensitivity](/ingredients/condition/weight-management). Additional mechanisms include [acetylcholine](/ingredients/condition/cognitive)sterase inhibition and potential GABA receptor interactions.

## Clinical Summary

Human clinical evidence for Peganum harmala is extremely limited, with most research conducted in animal models and cell cultures. Animal studies suggest potential blood sugar lowering effects at doses of 200-400mg/kg, but these findings cannot be extrapolated to humans. In vitro studies demonstrate significant MAO inhibition with IC50 values around 10-50 μM for harmine. No randomized controlled trials have evaluated safety or efficacy in human subjects.

## Nutritional Profile

Peganum harmala seeds contain approximately 3-6% total alkaloid content by dry weight, dominated by beta-carboline alkaloids: harmine (0.44-4.3% dry weight), harmaline (0.25-3.9% dry weight), and harmalol (0.1-0.4% dry weight), with tetrahydroharmine present in smaller trace amounts. Quinazoline alkaloids vasicine and vasicinone are present at approximately 0.1-0.3% combined. Crude protein content ranges from 18-25% dry weight, composed primarily of glutamic acid, aspartic acid, and arginine residue fractions. Crude fat content is approximately 8-15% dry weight, with linoleic acid (omega-6) and oleic acid comprising the majority of fatty acid fractions. Crude fiber is approximately 20-28% dry weight. Carbohydrate content is approximately 20-30% dry weight. Mineral content includes potassium (estimated 600-900 mg/100g dry weight), calcium (approximately 300-500 mg/100g), magnesium (approximately 150-250 mg/100g), iron (approximately 8-15 mg/100g), and zinc (approximately 3-6 mg/100g), though precise validated figures are limited in peer-reviewed literature. Flavonoids including rutin and isorhamnetin glycosides are present at low concentrations (estimated <0.5% dry weight). Bioavailability note: The beta-carboline alkaloids are rapidly absorbed orally but undergo significant first-pass hepatic [metabolism](/ingredients/condition/weight-management); harmaline is more rapidly metabolized than harmine. The MAOI activity of these alkaloids substantially affects bioavailability of co-ingested tryptamine compounds. As a non-conventional food ingredient consumed primarily as a spice or medicinal preparation in very small quantities (typically 0.1-1g per use), macronutrient contributions to daily intake are negligible in typical culinary applications.

## Dosage & Preparation

No clinically validated dosage ranges have been established for human use. Analytical studies report harmaline concentrations of 56.0 mg/g in seeds, 4.55 mg/g in fruits, and 0.54 mg/g in capsule walls, but safe human dosing remains unstudied. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Peganum harmala poses serious safety risks due to its MAO-inhibiting properties, potentially causing dangerous interactions with medications including SSRIs, SNRIs, and stimulants. Consumption may trigger hypertensive crisis when combined with tyramine-rich foods or certain drugs. The plant contains compounds that may cause nausea, vomiting, and hallucinations at higher doses. Pregnant and breastfeeding women should avoid use due to potential uterine stimulant effects and lack of safety data.

## Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses for Peganum harmala were identified in the available research. Current evidence is limited to pharmacological reviews of animal and in-vitro data, with researchers calling for clinical validation due to documented intoxication risks.

## Historical & Cultural Context

In Iranian and North African folk medicine, Peganum harmala has been used for centuries, with seeds, bark, and roots employed for various therapeutic purposes. The plant's beta-carboline alkaloids have been linked to these traditional therapeutic applications, though specific historical uses and duration are not quantified in available literature.

## Synergistic Combinations

Passionflower, St. John's Wort, Rhodiola, Ginkgo biloba, Ashwagandha

## Frequently Asked Questions

### What is the active compound in Peganum harmala?

The main active compounds are beta-carboline alkaloids including harmine (0.43-4.3%), harmaline (0.25-5.6%), and harmalol. These alkaloids are responsible for the MAO-inhibiting and psychoactive properties of Syrian rue.

### Can Peganum harmala help with depression?

While harmine and harmaline theoretically increase serotonin levels through MAO inhibition, no human clinical trials have tested Peganum harmala for depression. The plant's MAO-inhibiting effects could be dangerous when combined with antidepressant medications.

### Is Syrian rue safe to take with medications?

No, Peganum harmala is not safe with most medications due to its MAO-inhibiting properties. It can cause dangerous interactions with antidepressants, stimulants, certain pain medications, and foods high in tyramine, potentially leading to hypertensive crisis.

### What dose of Peganum harmala is used traditionally?

Traditional preparations typically use 1-3 grams of seeds, but no standardized or clinically validated dosing exists. Given the serious safety concerns and lack of human studies, therapeutic dosing cannot be recommended.

### Does Peganum harmala lower blood sugar?

Animal studies suggest potential blood sugar lowering effects through PPARγ activation, but human evidence is completely lacking. The plant should not be used for diabetes management due to safety risks and absence of clinical validation.

### What is the evidence quality for Peganum harmala's health benefits?

Most evidence for Peganum harmala comes from traditional use in Iranian and North African medicine or preliminary animal and in-vitro studies, with very limited human clinical trials. The mechanistic research on its monoamine oxidase inhibiting compounds and PPARγ pathway modulation is promising but does not yet constitute strong clinical validation. Current scientific evidence is insufficient to make definitive health claims, and more rigorous human studies are needed before recommending it for specific therapeutic purposes.

### Who should avoid taking Peganum harmala?

Peganum harmala should be avoided by pregnant and breastfeeding women due to lack of safety data and traditional use as an abortifacient in some cultures. Individuals taking serotonergic medications (SSRIs, SNRIs), stimulants, or other mood-altering drugs should not use it due to its monoamine oxidase inhibiting properties and serious interaction risk. People with uncontrolled blood pressure, heart conditions, or those sensitive to alkaloid-containing plants should consult a healthcare provider before use.

### What is the most bioavailable form of Peganum harmala?

Peganum harmala is traditionally prepared as a tea or decoction from seeds, though exact bioavailability data comparing different preparation methods in humans is not well-established. The alkaloid content and extraction efficiency may vary significantly depending on preparation temperature, duration, and seed source, affecting how much of the active compounds your body absorbs. Standardized extracts with verified alkaloid content may offer more consistent dosing than whole plant preparations, though clinical data comparing their bioavailability is limited.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*